IL265208A - Cell mast stabilizer for the treatment of hypercytokinemia and viral infection - Google Patents

Cell mast stabilizer for the treatment of hypercytokinemia and viral infection

Info

Publication number
IL265208A
IL265208A IL265208A IL26520819A IL265208A IL 265208 A IL265208 A IL 265208A IL 265208 A IL265208 A IL 265208A IL 26520819 A IL26520819 A IL 26520819A IL 265208 A IL265208 A IL 265208A
Authority
IL
Israel
Prior art keywords
hypercytokinemia
treatment
viral infection
mast cell
cell stabilizers
Prior art date
Application number
IL265208A
Other languages
English (en)
Hebrew (he)
Original Assignee
Emergo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergo Therapeutics Inc filed Critical Emergo Therapeutics Inc
Publication of IL265208A publication Critical patent/IL265208A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
IL265208A 2016-09-08 2019-03-07 Cell mast stabilizer for the treatment of hypercytokinemia and viral infection IL265208A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662385021P 2016-09-08 2016-09-08
PCT/US2017/050409 WO2018048989A1 (en) 2016-09-08 2017-09-07 Mast cell stabilizers for treatment of hypercytokinemia and viral infection

Publications (1)

Publication Number Publication Date
IL265208A true IL265208A (en) 2019-05-30

Family

ID=61281984

Family Applications (1)

Application Number Title Priority Date Filing Date
IL265208A IL265208A (en) 2016-09-08 2019-03-07 Cell mast stabilizer for the treatment of hypercytokinemia and viral infection

Country Status (15)

Country Link
US (5) US10501527B2 (enExample)
EP (1) EP3509596B1 (enExample)
JP (1) JP2019529541A (enExample)
KR (1) KR20190073365A (enExample)
CN (1) CN109952101A (enExample)
AU (2) AU2017325010A1 (enExample)
BR (1) BR112019004496A2 (enExample)
CA (1) CA3036230A1 (enExample)
ES (1) ES2988617T3 (enExample)
IL (1) IL265208A (enExample)
MX (1) MX389999B (enExample)
MY (1) MY204310A (enExample)
PH (1) PH12019500513A1 (enExample)
RU (1) RU2760682C2 (enExample)
WO (1) WO2018048989A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
KR20190044647A (ko) 2016-08-31 2019-04-30 더 제너럴 하스피탈 코포레이션 신경변성 질환과 관련된 신경-염증에서 대식세포/미세아교세포
KR20190073365A (ko) 2016-09-08 2019-06-26 이메르고 테라퓨틱스, 인코포레이티드 사이토카인 과분비 및 바이러스성 감염의 치료를 위한 비만 세포 안정화제
JP2019533018A (ja) 2016-10-18 2019-11-14 エマーゴ セラピューティクス，インク． 慢性炎症状態の処置の為の肥満細胞安定剤
WO2020051322A1 (en) * 2018-09-05 2020-03-12 The General Hospital Corporation Methods of treating cytokine release syndrome
CA3122989A1 (en) 2018-12-10 2020-06-18 The General Hospital Corporation Cromolyn esters and uses thereof
US20200268734A1 (en) * 2019-02-22 2020-08-27 Bridge Pharma, Inc. Methods of treatment of respiratory disorders
US10959992B2 (en) 2019-02-22 2021-03-30 Bridge Pharma Inc. Methods of treatment of asthma and COPD
US20230346848A1 (en) * 2020-03-06 2023-11-02 Figene, Llc Fibroblast and tlr activated fibroblast treatment of viral induced acute respiratory distress syndrome
JP2023520580A (ja) * 2020-04-06 2023-05-17 ザ ジェネラル ホスピタル コーポレイション コロナウイルス誘発炎症状態の処置方法
WO2023278381A1 (en) * 2021-06-29 2023-01-05 Bridge Pharma, Inc. Treatment of dermal cytokine storm syndromes

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878715B1 (en) 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
AU6165798A (en) 1997-02-18 1998-09-08 Bridge Pharma, Inc. Non-sedating histamine antagonist compounds, compositions and methods of use thereof
BR9807911A (pt) 1997-04-03 2000-02-22 Bridge Pharma Inc Compostos benzocicloheptatiofeno
US6207684B1 (en) * 1997-06-09 2001-03-27 Bridge Pharma, Inc. Compounds with combined antihistaminic and mast cell stabilizing activities, intended for ophthalmic use
CA2283603A1 (en) 1998-10-01 2000-04-01 Paul W. Behnke Forced closed-loop cooling for a submersible pump motor
AU782816B2 (en) 1999-09-13 2005-09-01 Bridge Pharma, Inc. Optically active isomers of ketotifen and therapeutically active metabolites thereof
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US20050249735A1 (en) 2000-08-07 2005-11-10 Centocor, Inc. Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US20030118670A1 (en) * 2001-07-11 2003-06-26 Smith C. Steven Novel composition and method for altering allergenic protein in the environment
US6680299B2 (en) 2001-07-27 2004-01-20 Enanta Pharmaceuticals, Inc. 4'-substituted leucomycins
US20060084695A1 (en) 2004-04-29 2006-04-20 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
JP2009517404A (ja) 2005-11-28 2009-04-30 メディミューン，エルエルシー Ｈｍｇｂ１および／またはｒａｇｅのアンタゴニストならびにその使用方法
CN104614873A (zh) 2006-09-29 2015-05-13 庄臣及庄臣视力保护公司 用于治疗眼变态反应性的方法和眼科装置
US20080139531A1 (en) 2006-12-04 2008-06-12 Alcon Manufacturing Ltd. Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair
WO2008153761A1 (en) * 2007-05-23 2008-12-18 Mastcell Pharmaceuticals, Inc. Methods
EP2214503A1 (en) 2007-10-15 2010-08-11 Revolymer Limited Solvent-free synthesis of amphiphilic polymeric material
CN101821989A (zh) 2007-12-24 2010-09-01 中兴通讯股份有限公司 一种光传输系统的通道共享保护方法及装置
CN101990437A (zh) * 2008-01-04 2011-03-23 阿尔康药品有限公司 稳定的环孢菌素水性组合物
WO2009142772A2 (en) 2008-05-23 2009-11-26 Mastcell Pharmaceuticals, Inc. Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
US8741930B2 (en) 2008-10-24 2014-06-03 Bridge Pharma, Inc. Treating xerophthalmia with norketotifen
WO2010059894A1 (en) 2008-11-21 2010-05-27 Bridge Pharma, Inc. Ocular formulations of norketotifen
CA2754996A1 (en) 2009-03-17 2010-09-23 Aciex Therapeutics, Inc. Ophthalmic formulations of ketotifen and methods of use
WO2010106016A1 (en) 2009-03-17 2010-09-23 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors
CA2780453A1 (en) 2009-12-02 2011-06-09 Bridge Pharma, Inc. Treating xerophthalmia with compounds increasing meibomian gland secretion
HUE033063T2 (hu) 2010-05-14 2017-11-28 Abbvie Inc IL-1 kötõ fehérjék
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
JP2014520847A (ja) 2011-07-13 2014-08-25 アッヴィ・インコーポレイテッド 抗ｉｌ−１３抗体を使用して喘息を治療するための方法および組成物
WO2014040112A1 (en) 2012-09-17 2014-03-20 Guina Research & Development Pty Ltd Electromagnetic turbine
US8557846B1 (en) 2012-10-23 2013-10-15 Bridge Pharma, Inc. Medicinal treatment of dermal diseases in dogs
US8778971B2 (en) 2012-10-23 2014-07-15 Bridge Pharma, Inc. Medicinal treatment of dermal diseases in companion animals
US20140120121A1 (en) 2012-10-30 2014-05-01 Bridge Pharma, Inc. Medicinal treatment of atopic inflammatory diseases
US20150272941A1 (en) 2012-10-30 2015-10-01 Bridge Pharma, Inc. Medicinal treatment of chronic pulmonary inflammatory diseases with norketotifen
US9347325B2 (en) 2012-10-31 2016-05-24 Solar Turbines Incorporated Damper for a turbine rotor assembly
JP6084473B2 (ja) 2013-02-01 2017-02-22 日立オートモティブシステムズ株式会社 複合センサ
US9439895B2 (en) 2013-08-06 2016-09-13 Bridge Pharma, Inc. Methods of treating pruritic conditions mediated through non-histaminergic mechanisms in diabetic patients
US9345697B2 (en) 2013-08-06 2016-05-24 Bridge Pharma, Inc. Methods of treatment of non-histaminic pruritus
US9138431B2 (en) * 2013-08-06 2015-09-22 Bridge Pharma, Inc. Methods of treatment of histamine H-4 receptor-related pruritus
WO2015120389A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Mast cell stabilizers treatment for systemic disorders
US10293352B2 (en) 2015-02-13 2019-05-21 Kärcher North America, Inc. Hand held fluid dispensing apparatus
CA2976369A1 (en) 2015-02-13 2016-08-18 Yale University Biaryltriazole inhibitors of macrophage migration inhibitory factor
WO2017035418A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for treatment of immune and inflammatory disorders
US9694003B2 (en) 2015-10-15 2017-07-04 Bridge Pharma, Inc. Formulations and methods for treating high intraocular pressure
KR20190073365A (ko) 2016-09-08 2019-06-26 이메르고 테라퓨틱스, 인코포레이티드 사이토카인 과분비 및 바이러스성 감염의 치료를 위한 비만 세포 안정화제
JP2019533018A (ja) 2016-10-18 2019-11-14 エマーゴ セラピューティクス，インク． 慢性炎症状態の処置の為の肥満細胞安定剤

Also Published As

Publication number Publication date
CN109952101A (zh) 2019-06-28
AU2017325010A1 (en) 2019-03-28
US20180066039A1 (en) 2018-03-08
KR20190073365A (ko) 2019-06-26
ES2988617T3 (es) 2024-11-21
AU2023204000A1 (en) 2023-07-13
PH12019500513A1 (en) 2019-05-27
MY204310A (en) 2024-08-22
US20190085057A1 (en) 2019-03-21
EP3509596A1 (en) 2019-07-17
US10494420B2 (en) 2019-12-03
US10787502B2 (en) 2020-09-29
RU2019110150A (ru) 2020-10-08
EP3509596B1 (en) 2024-07-03
MX2019002781A (es) 2019-09-04
JP2019529541A (ja) 2019-10-17
EP3509596A4 (en) 2020-05-06
RU2760682C2 (ru) 2021-11-29
US20180072796A1 (en) 2018-03-15
CA3036230A1 (en) 2018-03-15
US20200055926A1 (en) 2020-02-20
RU2019110150A3 (enExample) 2020-12-18
EP3509596C0 (en) 2024-07-03
WO2018048989A1 (en) 2018-03-15
MX389999B (es) 2025-03-11
US20200055927A1 (en) 2020-02-20
US10501527B2 (en) 2019-12-10
BR112019004496A2 (pt) 2019-05-28
US10160796B2 (en) 2018-12-25
US11072648B2 (en) 2021-07-27

Similar Documents

Publication Publication Date Title
IL265208A (en) Cell mast stabilizer for the treatment of hypercytokinemia and viral infection
ZA201903906B (en) Phosphoramidates for the treatment of hepatitis b virus
IL245436A0 (en) New dihydroquinolizinones for the treatment and prevention of hepatitis b virus infection
GB2573664B (en) Viral methods of T cell therapy
IL246449B (en) Conjugated 6-heteroaryl dihydropyrimidines for the treatment and prevention of hepatitis b virus infection
PL3554631T3 (pl) Leczenie pacjentów polami ttfields ze zoptymalizowanymi pozycjami elektrod z wykorzystaniem odkształcalnych matryc
ZA201507840B (en) 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
IL249660A0 (en) Methods for treating hepatitis b virus and hepatitis d virus infections
ZA201705634B (en) Quinoline derivatives for use in the treatment or prevention of viral infection
PL3137078T3 (pl) Leczenie zakażenia wirusem zapalenia wątroby typu delta
IL292054A (en) Compositions for treatment of abnormal cell growth
IL258237A (en) Treatment of viral conjunctivitis using renfiranase and / or empinase
EP3226973A4 (en) Treatment of hepatitis delta virus infection
GB201615035D0 (en) Treatment and prevention of viral infection
IL269146A (en) Infected cell cultures
ZA201604784B (en) Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
GB201520019D0 (en) The genome and self-evolution of AI
EP3241555A4 (en) Use of pyrophosphate ion analogues for the treatment of hpv infection